List of Santen Pharmaceutical patents

Patents where

Current Assignee

Name

Santen Pharmaceutical

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8663639 Formulations for treating ocular diseases and conditions	Patent 8663639 was granted and assigned to Santen Pharmaceutical on March, 2014 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	8663639	March 4, 2014
‌ US Patent 8367097 Liquid formulations for treatment of diseases or conditions	Patent 8367097 was granted and assigned to Santen Pharmaceutical on February, 2013 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	8367097	February 5, 2013
‌ US Patent 8193187 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity	Patent 8193187 was granted and assigned to Santen Pharmaceutical on June, 2012 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	8193187	June 5, 2012
‌ US Patent 8927005 Liquid formulations for treatment of diseases or conditions	Patent 8927005 was granted and assigned to Santen Pharmaceutical on January, 2015 by the United States Patent and Trademark Office.	Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	8927005	January 6, 2015
‌ US Patent 7325440 Hole inspection system for a pierced container	Patent 7325440 was granted and assigned to Santen Pharmaceutical on February, 2008 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	7325440	February 5, 2008
‌ US Patent 11324829 Antiseptic agent comprising meglumine or salt thereof	Patent 11324829 was granted and assigned to Santen Pharmaceutical on May, 2022 by the United States Patent and Trademark Office.	Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	11324829	May 10, 2022
‌ US Patent 7358255 Therapeutic agent for keratoconjunctival disorder	Patent 7358255 was granted and assigned to Santen Pharmaceutical on April, 2008 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	7358255	April 15, 2008
‌ US Patent 7503909 Instillation container with level-difference portion	Patent 7503909 was granted and assigned to Santen Pharmaceutical on March, 2009 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	7503909	March 17, 2009
‌ US Patent 7832594 Liquid storage container with bottom filter	Patent 7832594 was granted and assigned to Santen Pharmaceutical on November, 2010 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	7832594	November 16, 2010
‌ US Patent 11013731 Intratumoral administration of sirolimus for treatment of prostate cancer	Patent 11013731 was granted and assigned to Santen Pharmaceutical on May, 2021 by the United States Patent and Trademark Office.	Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	11013731	May 25, 2021
‌ US Patent 7438704 Open instillation container and method of manufacturing the container	Patent 7438704 was granted and assigned to Santen Pharmaceutical on October, 2008 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	7438704	October 21, 2008
‌ US Patent 11446273 Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor	Patent 11446273 was granted and assigned to Santen Pharmaceutical on September, 2022 by the United States Patent and Trademark Office.	Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	11446273	September 20, 2022
‌ US Patent 11285081 Sealed preparation container and use for same	Patent 11285081 was granted and assigned to Santen Pharmaceutical on March, 2022 by the United States Patent and Trademark Office.	Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	11285081	March 29, 2022
‌ US Patent 9539204 Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage	Patent 9539204 was granted and assigned to Santen Pharmaceutical on January, 2017 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	9539204	January 10, 2017
‌ US Patent 11331311 Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound	Patent 11331311 was granted and assigned to Santen Pharmaceutical on May, 2022 by the United States Patent and Trademark Office.	Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	11331311	May 17, 2022
‌ US Patent 11400080 Use of sirolimus to treat exudative age-related macular degeneration with persistent edema	Patent 11400080 was granted and assigned to Santen Pharmaceutical on August, 2022 by the United States Patent and Trademark Office.	Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	11400080	August 2, 2022
‌ US Patent 7491739 TNF-α production inhibitors	Patent 7491739 was granted and assigned to Santen Pharmaceutical on February, 2009 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	7491739	February 17, 2009
‌ US Patent 9999594 Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage	Patent 9999594 was granted and assigned to Santen Pharmaceutical on June, 2018 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	9999594	June 19, 2018
‌ US Patent 11419880 Ursodeoxycholic acid-containing agent for treating or preventing presbyopia		Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	11419880	August 23, 2022
‌ US Patent 8486960 Formulations and methods for vascular permeability-related diseases or conditions	Patent 8486960 was granted and assigned to Santen Pharmaceutical on July, 2013 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	8486960	July 16, 2013
‌ US Patent 8975256 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity	Patent 8975256 was granted and assigned to Santen Pharmaceutical on March, 2015 by the United States Patent and Trademark Office.	Santen Pharmaceutical	Santen Pharmaceutical	United States Patent and Trademark Office	8975256	March 10, 2015
‌ US Patent 8664221 Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent	Patent 8664221 was granted and assigned to Santen Pharmaceutical on March, 2014 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	8664221	March 4, 2014
‌ US Patent 8426406 Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group	Patent 8426406 was granted and assigned to Santen Pharmaceutical on April, 2013 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	8426406	April 23, 2013
‌ US Patent 8198271 Thiophenediamine derivative having urea structure	Patent 8198271 was granted and assigned to Santen Pharmaceutical on June, 2012 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	8198271	June 12, 2012
‌ US Patent 8207194 Compounds having a 4-pyridylalkylthio group as a substituent	Patent 8207194 was granted and assigned to Santen Pharmaceutical on June, 2012 by the United States Patent and Trademark Office.		Santen Pharmaceutical	United States Patent and Trademark Office	8207194	June 26, 2012

Results per page:

82 results

0 selected

82 results

0 selected